Encyclopedia of Cancer

Living Edition
| Editors: Manfred Schwab

Bacillus Calmette-Guérin

  • Sven BrandauEmail author
Living reference work entry
DOI: https://doi.org/10.1007/978-3-642-27841-9_514-2



Bacillus Calmette-Guérin (BCG) is a mycobacterium belonging to the Mycobacterium tuberculosis complex. It is a live attenuated organism and generally nonpathogenic for healthy human subjects. Originally developed as a vaccine against tuberculosis, since the mid-1970s, it is increasingly used as a successful active immunotherapeutic agent in the treatment of nonmuscle-invasive bladder cancer.


Microbiological Background on BCG and Tuberculosis Vaccination

BCG is an attenuated derivative of virulent Mycobacterium bovis (M. bovis), the causative pathogen of bovine tuberculosis. The name of BCG acknowledges the contributions of two French researchers Albert Calmette, a microbiologist, and Jean-Marie Camille Guérin, a veterinarian. Those two, between 1908 and 1921, passaged a virulent strain of M. bovisin an attempt to generate a vaccine against tuberculosis in humans. By using a continuous in vitro passage and a special...


Bladder Cancer Bladder Wall Mycobacterium Bovis Intravesical Instillation Mycobacterium Tuberculosis Complex 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.


  1. Brandau S, Suttmann H (2007) Thirty years of BCG immunotherapy for non-muscle invasive bladder cancer: a success story with room for improvement. Biomed Pharmacother 61(6):299–305CrossRefPubMedGoogle Scholar
  2. Huber CH, Wolfel T (2004) Immunotherapy of cancer: from vision to standard clinical practice. J Cancer Res Clin Oncol 130(7):367–374CrossRefPubMedGoogle Scholar
  3. Mostowy S, Tsolaki AG, Small PM et al (2003) The in vitro evolution of BCG vaccines. Vaccine 21(27–30):4270–4274CrossRefPubMedGoogle Scholar
  4. Seya T, Akazawa T, Uehori J et al (2003) Role of toll-like receptors and their adaptors in adjuvant immunotherapy for cancer. Anticancer Res 23(6a):4369–4376PubMedGoogle Scholar
  5. Sylvester RJ, Meijden AP, van derLamm DL (2002) Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 168(5):1964–1970CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  1. 1.Department of OtorhinolaryngologyUniversity Duisburg-EssenEssenGermany